08:41 IST
NSE
Regulatory Approval
Glenmark Pharmaceuticals Regulatory Approval
Glenmark received U.S. FDA approval to expand the use of its RYALTRIS nasal spray to pediatric patients aged 6 to less than 12 years.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,293.50
- Market cap
- ₹64,728 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.0×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 7Product Launch 6Financial Results 4Other Announcement 3Business Update 3Results Update 2Regulatory Approval 2Legal & Regulatory 2Board Meeting Date 2Annual General Meeting 2Merger & Restructuring 1Management Change 1Employee Stock Options 1Dividend 1Debt & Borrowing 1Credit Rating 1
Time
2 announcements with these filters
08:50 IST
NSE
Regulatory Approval
Glenmark Pharmaceuticals Regulatory Approval
Glenmark Pharmaceuticals received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg. The product targets a market with annual sales of approximately ₹544.64 Crore ($59.2 million). This approval strengthens Glenmark's women's healthcare portfolio in the U.S. market.
- Value
- ₹491.7 Cr